Effect of Inhibiting Upstream Aryl Hydrocarbon Receptor Nuclear Translocator on the TCDD-induced Non-alcoholic Fatty Liver Disease

被引:0
|
作者
Ye, Yufei [1 ]
机构
[1] Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada
来源
2021 8TH INTERNATIONAL CONFERENCE ON BIOINFORMATICS RESEARCH AND APPLICATIONS, ICBRA 2021 | 2021年
关键词
NAFLD; TCDD; SLC46A3; AhR; ARNT;
D O I
10.1145/3487027.3487032
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) from industrial by-product is a dominant trigger of Non-alcoholic fatty liver disease (NAFLD) that induces an excess triglycerides buildup within the liver. This paper discusses whether knockout of upstream Aryl hydrocarbon receptor nuclear translocator (ARNT) relieves the liver burden in preventing abnormal lipid accumulation after TCDD exposure. This experiment utilizes two models (1) in vivo mice model and (2) in vitro human normal liver cell line model. The ARNT gene is knockout by CRISPR, and the expression of AhR-ARNT complex is detected. Intracellular copper transport assay, mitochondrial OCR analysis, liver function test and histology are then used to observe the ARNT-/- gene regulation and liver cell responses in both models. The most possible result is that ARNT knockout inhibits the TCDD-induced liver toxicity at the initial binding site without affecting the downstream gene regulation; both in vitro and in vivo models present a healthy liver state. The results will contribute crucial information on the TCDD-elicited gene regulation mechanism inside the liver cell, providing detailed environmental toxicant-triggered model studies relate to NAFLD. Prospective studies should focus on investigating the in detail potential side effects of ARNT knockout on the liver and other relative organs.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [31] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [32] Metabolic drivers of non-alcoholic fatty liver disease
    Bence, Kendra K.
    Birnbaum, Morris J.
    MOLECULAR METABOLISM, 2020, 50
  • [33] Transient elastography in non-alcoholic fatty liver disease
    Abenavoli, Ludovico
    Beaugrand, Michel
    ANNALS OF HEPATOLOGY, 2012, 11 (02) : 172 - 178
  • [34] The Role of Non-Alcoholic Fatty Liver Disease in Infections
    Krznaric, Juraj
    Vince, Adriana
    LIFE-BASEL, 2022, 12 (12):
  • [35] Gut Dysfunction and Non-alcoholic Fatty Liver Disease
    Grabherr, Felix
    Grander, Christoph
    Effenberger, Maria
    Adolph, Timon Erik
    Tilg, Herbert
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [36] The fecal mycobiome in non-alcoholic fatty liver disease
    Demir, Munevver
    Lang, Sonja
    Hartmann, Phillipp
    Duan, Yi
    Martin, Anna
    Miyamoto, Yukiko
    Bondareva, Marina
    Zhang, Xinlian
    Wang, Yanhan
    Kasper, Philipp
    Bang, Corinna
    Roderburg, Christoph
    Tacke, Frank
    Steffen, Hans-Michael
    Goeser, Tobias
    Kruglov, Andrey
    Eckmann, Lars
    Starkel, Peter
    Fouts, Derrick E.
    Schnabl, Bernd
    JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 788 - 799
  • [37] The Natural Course of Non-Alcoholic Fatty Liver Disease
    Bertot, Luis Calzadilla
    Adams, Leon Anton
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
  • [38] Non-alcoholic fatty liver disease: a massive problem
    Day, Christopher P.
    CLINICAL MEDICINE, 2011, 11 (02) : 176 - 178
  • [39] Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
    Hajduch, Eric
    Lachkar, Floriane
    Ferre, Pascal
    Foufelle, Fabienne
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 19
  • [40] Treatment regimens for non-alcoholic fatty liver disease
    Lam, Brian P.
    Younossi, Zobair M.
    ANNALS OF HEPATOLOGY, 2009, 8 : S51 - S59